secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2022-04-26T23:59:59+00:00
Accession:  0001213900-22-021526
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma board nominee Maria Maccecchini; director Leslie Kreis not standing for reelection
--------------------------------------------------------------------------------

- Leslie W. Kreis, Jr. will not stand for reelection at the June 8, 2022 annual meeting.
- Maria L. Maccecchini, Ph.D., CEO of Annovis Bio (ANVS), nominated to the board.
- She brings over 30 years biopharma experience in neurodegenerative disease and drug development.
- Kreis served since 2019; CEO Panna Sharma thanked him for guiding Lantern through IPO and growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022021526/0001213900-22-021526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022021526/ea158857-8k_lantern.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-021526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer